COMMUNIQUÉS West-GlobeNewswire

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
12/05/2026
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline [...]
PayZen Report: Healthcare Financial Pressures Mount as 73% of Systems Elevate Patient Payment Balances to a Top Priority
12/05/2026
PayZen’s State of Healthcare Affordability: The Provider Perspective 2026 report highlights rising focus on better financial experiences, limited payment flexibility, and AI acceleration SAN FRANCISCO, May 12, 2026 ( [...]
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis – – Expect to report topline data from both Phase 2 [...]
LiveWorld Reports First Quarter 2026 Financial Results
12/05/2026
LiveWorld continues to increase its AI investment CAMPBELL, Calif. and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for first quarter 2026. Three [...]
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
12/05/2026
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable [...]
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
12/05/2026
Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session Company to host investor conference call and webcast during EHA 2026 on Saturday, June [...]
JenaValve Appoints Dave Haan as Vice President of Clinical Affairs
12/05/2026
IRVINE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy ® Transcatheter Heart Valve (THV) System, today announced the appointment of Dave Haan as Vice [...]
PrognomiQ Announces Breakthrough Results for the Early Detection of Lung Cancer in Ongoing Real-World Study for Its Novel Blood Test
12/05/2026
ProVue Lung blood test detects lung cancers with 89% overall sensitivity and 83% sensitivity at stage I, the earliest and most treatable stage SAN MATEO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- PrognomiQ , a healthcare [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Four Winners Selected in PerfectServe’s 2026 Nurses of Note Awards Program
12/05/2026
Winners are nurse leaders whose work focuses on mentorship for new nurses, neonatal care and education, and better perioperative care team communication MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- PerfectServe®, a leading [...]
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings Preclinical data from [...]
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
12/05/2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell [...]
Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research
12/05/2026
Grant program expands access to advanced single-domain antibody technologies to support the research and development of next-generation therapies BOSTON and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Fortis Life Sciences [...]
BlossomHill Therapeutics to Present Initial Clinical Dose Escalation Data from the Phase 1/1b Trial of BH-30236 in Patients with R/R AML or HR-MDS at EHA2026
12/05/2026
Treatment with BH-30236, a novel CLK inhibitor, was generally well tolerated as monotherapy and in combination with venetoclax Preliminary anti-leukemic activity observed, including patients that were previously treated [...]
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
12/05/2026
Data will reflect the functional characterization of EVX-04 Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing [...]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform
12/05/2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) [...]
Cellectis présentera des données cliniques sur lasmé-cel et éti-cel au congrès annuel de l’EHA 2026
12/05/2026
NEW YORK, 12 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour développer des [...]
Adagene to Participate in Two Upcoming Investor Conferences
12/05/2026
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today [...]
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
12/05/2026
Vancouver, Canada, May 12, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]

Pages